GlassScriptPhysician profile
Zacharias Chasin
NPI 1740447382
$1,614.80
in general payments reported to CMS, 2019-2025
17 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.11 · 2024: $619 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.07 | 2024-2025 | |
| Novo Nordisk INC | $388.37 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $178.72 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Allergan, INC. | $72.11 | 2019 | |
| Exact Sciences Corporation | $51.90 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.13 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $36.81 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $36.02 | 2025 | |
| Seqirus USA INC | $32.08 | 2025 | Flucelvax, Fluad |
| Corcept Therapeutics | $30.62 | 2025 | Korlym |
| Renalytix Ai, INC. | $30.51 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Bayer Healthcare Pharmaceuticals INC. | $23.50 | 2025 | |
| Ibsa Pharma INC. | $19.35 | 2025 | Tirosint, Flector, Licart |
| E.R. Squibb & Sons, L.L.C. | $18.41 | 2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $17.37 | 2025 | Airsupra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.02 | 2024 | Bexsero, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.81 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zacharias Chasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.